This study was aimed to assess whether serum or urine UCH-L1 levels are a reliable marker of brain damage in patients with WMLs.
To determine if sex differences in glucose uptake, a marker of brain activity, are present in brain regions that facilitate walking performance in persons with multiple sclerosis (MS).
The randomized study, conducted in 2009, asked 47 participants to undergo positron emission tomography - or PET - scans, which measure brain glucose metabolism, a marker of brain activity.
The aim of the present study was to evaluate whether serum UCH-L1 levels are a reliable marker of brain damage and the association of UCH-L1 with outcome.
We observed a significant increase in binding of [11C]DPA-713 thetranslocatorator protein (TSPO), a marker of brain injury and repair, in several brain regions, such as the supramarginal gyrus and right amygdala, in 9 former NFL players compared to 9 age-matched, healthy controls.
The PET radioligand [11C]PBR28 binds to the translocator protein (TSPO), which is expressed in glial cells and regarded as a marker of brain immune function.
These changes may indicate an imbalance between the serotonin and kynurenine pathways and serve as a molecular imaging marker of brain tumor-associated depression.
Altered tryptophan metabolism in non-tumoral brain, measured by PET, may be a novel imaging marker of brain tumor-associated depression.
The S100B protein is an indicator of glial activation and/or death; thus, it is a nonspecific marker of brain injury [51] The S100B protein has been shown to be elevated in patients with delirium [52].
